Bivalirudin - Wikipedia Bivalirudin, sold under the brand names Angiomax and Angiox, among others, is a specific and reversible direct thrombin inhibitor (DTI) [2] Chemically, it is a synthetic congener of the naturally occurring drug hirudin, found in the saliva of the medicinal leech Hirudo medicinalis
Bivalirudin Uses, Side Effects Warnings - Drugs. com What is bivalirudin? Bivalirudin is an anticoagulant (thrombin inhibitor) that helps prevent the formation of blood clots Bivalirudin is used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty (to open blocked arteries)
label - Food and Drug Administration Among 494 subjects who received bivalirudin in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests
Bivalirudin (intravenous route) - Side effects uses - Mayo Clinic Bivalirudin is used together with aspirin to decrease the clotting ability of the blood and to help prevent harmful clots from forming in the blood vessels It is used in patients who are having certain heart and blood vessel procedures, such as coronary angioplasty
DailyMed - BIVALIRUDIN injection, solution Bivalirudin Injection is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia and
Bivalirudin for Injection - Pfizer Bivalirudin is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) (1)
Bivalirudin – UW Medicine Anticoagulation Services Bivalirudin elevates prothrombin time INR For an accurate assessment of warfarin effect in patients on current bivalirudin, use Chromogenic Factor X monitoring
BIVALIRUDIN DOSING AND MONITORING GUIDELINE To provide standardized dosing and monitoring guidelines for patients receiving bivalirudin therapy for anticoagulation The guidelines provided below are recommendations to assist the medical staff in appropriate administration and monitoring of bivalirudin therapy